Similar articles

• Reserpine and the medical marketplace.

  Lederle FA, Applegate WB, Grimm RH Jr. Lederle FA, et al. Arch Intern Med. 1993 Mar 22;153(6):705-6. Arch Intern Med. 1993. PMID: 8447707 Review. No abstract available.
• A randomised crossover comparison of reserpine and sustained-release nifedipine in hypertension.

  Manyemba J. Manyemba J. Cent Afr J Med. 1997 Dec;43(12):344-9. Cent Afr J Med. 1997. PMID: 9631111 Clinical Trial.
• Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension.

  Hilleman DE, Mohiuddin SM, Lucas BD Jr, Stading JA, Stoysich AM, Ryschon K. Hilleman DE, et al. Clin Ther. 1994 Jan-Feb;16(1):88-102; discussion 87. Clin Ther. 1994. PMID: 7911403
• Diltiazem for treatment of essential hypertension: a double-blind controlled study with reserpine.

  Ogawa K, Ban M, Ito T, Watanabe T, Kobayashi T, Yamazaki N, Suzuki Y. Ogawa K, et al. Clin Ther. 1984;6(6):844-53. Clin Ther. 1984. PMID: 6391669 Clinical Trial.
• Hypertension--low cost chemotherapy.

  Carr AA. Carr AA. J Med Assoc Ga. 1983 Sep;72(9):651-3. J Med Assoc Ga. 1983. PMID: 6355352 Review. No abstract available.